best glp-1 drug 2025 What to Make of the Coverage and Cost Landscape Saba GLP-1 – Best GLP-1

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPAKIDNEY trial

Robert Kushner: We are really living in the GLP-1 generation now

Beyond potential direct neuroprotective effects, these medications address several modifiable risk factors for dementia

They showed better effects in improving mouse motor function scores, promoting the repair and regeneration of synapses or dopaminergic neurons (TH+, GDNF, synaptophysin), and inhibiting neuroinflammatory responses (IBA-1, IL-2) compared to liraglutide and DA-JC1, highlighting the advantage of targeting more sites

[DOI] [PMC free article] [PubMed] [Google Scholar] [10].Rasmussen L, Poulsen CW, Kampmann U, Smedegaard SB, Ovesen PG, Fuglsang J

They are not cures for the disease of obesity, Le Roux said